Article

Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes

Laboratoire d'Hématologie Hôpital Nord, CHU de Saint-Etienne, France.
Cytometry Part B Clinical Cytometry (Impact Factor: 2.28). 01/2008; 74(1):17-24. DOI: 10.1002/cyto.b.20371
Source: PubMed

ABSTRACT The knowledge of normal marrow is mandatory to assess the malignant counterpart of normal cells and define leukemia-associated immunophenotypes (LAIPs). In this study, the expression of a variety of antigens expressed in normal and postchemotherapy bone marrow (BM) was analyzed to provide a frame of reference for the identification of myeloid LAIPs.
Multiparameter four- and six-color flow cytometry was used to define antigen combinations totally absent or present at very minimal levels in marrow cells of normal individuals (n = 20) and patients receiving chemotherapy for acute lymphoblastic leukemia (n = 20). Immature (blast) cells were gated according to CD45/SSC properties. Fifty-three acute myeloid leukemia (AML) samples were studied in six-color combinations.
In six-color flow cytometry, 47 phenotypes were totally absent from blast gate in all normal samples. Forty-one other phenotypes were identified in less than 0.05% of blast cells. There was no difference between normal and postchemotherapy BMs. The four-color panel allowed to identify only 30 phenotypes present at a frequency <0.05%. Using the six-color panel, 58% of the absent or infrequent phenotypes in normal BM were found in at least one of 53 AML samples. All AML cases exhibited at least one LAIP.
Our results show that the ability to distinguish leukemic from healthy cells is considerably increased by a six-color approach. Furthermore, these absent or infrequent phenotypes in normal BM are identified in AML and can be utilized for minimal residual disease study.

Download full-text

Full-text

Available from: Nathalie Nadal, Jun 27, 2015
1 Follower
 · 
91 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective and subjective measures were obtained for a 4-band, 16-kbit/s sub-band coder utilizing adaptive quantizers with fixed and dynamic bit allocations. Objective measures indicated that block quantization (block companded PCM with a Gaussian probability density function, BCPCM-G) with dynamic bit allocation is slightly better than an adaptive differential PCM with a variable predictor (ADPCM-V) and fixed bit allocation, but outperforms ADPCM with a fixed predictor and fixed bit allocation (ADPCM-F) by 4-5 dB. Subjective measures, however, indicated that ADPCM-V has about 6-dB advantage over BCPCM-G. A comparison between ADPCM-V and ADPCM-F indicated that adaptive prediction provides a 4-5 dB objective gain and 16-dB subjective gain over fixed prediction. Further, all listeners preferred ADPCM-V over BCPCM-G and ADPCM-F, and 85% preferred BCPCM-G over ADPCM-F.
    Acoustics, Speech, and Signal Processing, IEEE International Conference on ICASSP '82.; 06/1982
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiparameter flow cytometry has become an essential tool for monitoring response to therapy in hematological malignancies, including B-cell chronic lymphoproliferative disorders (B-CLPD). However, depending on the expertise of the operator minimal residual disease (MRD) can be misidentified, given that data analysis is based on the definition of expert-based bidimensional plots, where an operator selects the subpopulations of interest. Here, we propose and evaluate a probabilistic approach based on pattern classification tools and the Bayes theorem, for automated analysis of flow cytometry data from a group of 50 B-CLPD versus normal peripheral blood B-cells under MRD conditions, with the aim of reducing operator-associated subjectivity. The proposed approach provided a tool for MRD detection in B-CLPD by flow cytometry with a sensitivity of < or =8 x 10(-5) (median of < or =2 x 10(-7)). Furthermore, in 86% of B-CLPD cases tested, no events corresponding to normal B-cells were wrongly identified as belonging to the neoplastic B-cell population at a level of < or =10(-7). Thus, this approach based on the search for minimal numbers of neoplastic B-cells similar to those detected at diagnosis could potentially be applied with both a high sensitivity and specificity to investigate for the presence of MRD in virtually all B-CLPD. Further studies evaluating its efficiency in larger series of patients, where reactive conditions and non-neoplastic disorders are also included, are required to confirm these results.
    Cytometry Part A 12/2008; 73A(12):1141-50. DOI:10.1002/cyto.a.20638 · 3.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this review is to evaluate recent immunophenotype knowledge of hematopoietic stem cells and their restricted progenies committed to myeloid lineage - common myeloid progenitors, myelo-monocytic progenitors, megakaryo-erythroid progenitors and granulocyte progenitors up to mature neutrophil granulocyte. This study evaluates also recent knowledge of immunophenotype of leukemic stem cells and their more differentiated progeny committed to myeloid lineage - acute myeloid leukemia blast cells with regard to their phenotypic similarity to normal stem and granulocyte committed progenitor cells. Improved knowledge of normal stem and progenitor cells phenotypes, identifying new leukemia-specific markers, searching for aberrant marker expression and evaluation of aberrant intensity or combination of various marker expressions is important for distinguishing normal cells from their malignant counterpart in view of the diagnostics of leukemias or follow-up of minimal residual disease.
    Neoplasma 01/2010; 57(5):392-400. DOI:10.4149/neo_2010_05_392 · 1.64 Impact Factor